Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
Parker B, Ward T, Hayward O, Jacob I, Arthurs E, Becker D, Anderson SJ, Chounta V, Van de Velde N. Parker B, et al. Among authors: chounta v. PLoS One. 2021 Feb 2;16(2):e0245955. doi: 10.1371/journal.pone.0245955. eCollection 2021. PLoS One. 2021. PMID: 33529201 Free PMC article.
Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries.
Akinwunmi B, Buchenberger D, Scherzer J, Bode M, Rizzini P, Vecchio F, Roustand L, Nachbaur G, Finkielsztejn L, Chounta V, Van de Velde N. Akinwunmi B, et al. Among authors: chounta v. Sex Transm Infect. 2021 Dec;97(8):566-573. doi: 10.1136/sextrans-2020-054648. Epub 2021 Feb 25. Sex Transm Infect. 2021. PMID: 33632889
Adherence to oral antiretroviral therapy in Canada, 2010-2020.
Angel JB, Freilich J, Arthurs E, Ban JK, Lachaine J, Chounta V, Harris M. Angel JB, et al. Among authors: chounta v. AIDS. 2023 Nov 1;37(13):2031-2040. doi: 10.1097/QAD.0000000000003648. Epub 2023 Jul 15. AIDS. 2023. PMID: 37418513 Free PMC article.
Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.
Punekar YS, Parks D, Joshi M, Kaur S, Evitt L, Chounta V, Radford M, Jha D, Ferrante S, Sharma S, Van Wyk J, de Ruiter A. Punekar YS, et al. Among authors: chounta v. HIV Med. 2021 Jul;22(6):423-433. doi: 10.1111/hiv.13050. Epub 2021 Feb 2. HIV Med. 2021. PMID: 33529489 Free PMC article.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, Degen O, García JG, Morell EB, Tan DHS, D'Amico R, Dorey D, Griffith S, Thiagarajah S, St Clair M, Van Solingen-Ristea R, Crauwels H, Ford SL, Patel P, Chounta V, Vanveggel S, Cutrell A, Van Eygen V, Vandermeulen K, Margolis DA, Smith KY, Spreen WR. Orkin C, et al. Among authors: chounta v. Lancet HIV. 2021 Apr;8(4):e185-e196. doi: 10.1016/S2352-3018(20)30340-4. Lancet HIV. 2021. PMID: 33794181 Clinical Trial.
21 results